• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    KKR & Co. Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    4/24/26 5:17:49 PM ET
    $KKR
    Investment Managers
    Finance
    Get the next $KKR alert in real time by email
    false000140491200014049122026-04-212026-04-210001404912kkr:Four625SubordinatedNotesDue2061OfKKRGroupFinanceCoIXLLCMember2026-04-212026-04-210001404912kkr:Six875SubordinatedNotesDue2065Member2026-04-212026-04-210001404912kkr:Six25SeriesDMandatoryConvertiblePreferredStockMember2026-04-212026-04-210001404912us-gaap:CommonStockMember2026-04-212026-04-21

    graphic
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549



    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): April 21, 2026
     
    KKR & Co. Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware
    001-34820
    88-1203639
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)
     
    30 Hudson Yards
    New York, NY 10001
    Telephone: (212) 750-8300
     
    (Address, zip code, and telephone number, including
    area code, of registrant’s principal executive office.)
     
    NOT APPLICABLE
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading symbol(s)
    Name of each exchange on which registered
    Common Stock
    KKR
    New York Stock Exchange
    6.25% Series D Mandatory Convertible Preferred Stock
    KKR PR D
    New York Stock Exchange
    4.625% Subordinated Notes due 2061 of KKR Group Finance Co. IX LLC
    KKRS
    New York Stock Exchange
    6.875% Subordinated Notes due 2065
    KKRT
    New York Stock Exchange
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ☐
    Emerging growth company
     
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
     


    Item 5.07.
    Submission of Matters to a Vote of Security Holders
     
    On April 21, 2026, KKR & Co. Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders considered four proposals relating to amendments to the Second Amended and Restated Certificate of Incorporation (the “Existing Charter”) and one proposal relating to adjournment, each of which is described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on February 27, 2026 (the “Proxy Statement”).

    Each of Proposals 2, 3, 4, and 5, relating to amendments to the Existing Charter and adjournment, were approved by the stockholders.

    Pursuant to the Company’s Second Amended and Restated Bylaws and in accordance with stockholder approval of Proposal 5, the Special Meeting was adjourned with respect to Proposal 1. Proposal 1 requires the affirmative vote of the holders of at least 90% of the Company’s outstanding common stock to be approved and is a proposal to eliminate the supermajority voting requirement to amend certain provisions of the Existing Charter.

    The Special Meeting will be adjourned until May 21, 2026 at 2:00 P.M., Eastern Time (the “Reconvened Meeting”). The Reconvened Meeting will be held via live webcast on the internet at www.virtualshareholdermeeting.com/KKR2026SM. Holders of record of the Company’s common stock and the non-economic Series I preferred stock as of the close of business on February 24, 2026 will be entitled to attend and vote on Proposal 1 at the Reconvened Meeting using the procedures set forth in the Proxy Statement.

    The preliminary voting results of our common stockholders at the time of the Special Meeting for Proposal 1 and the final voting results of our common stockholders for each matter submitted to a vote of stockholders at the Special Meeting are set forth below:

    Proposal 1. An amendment to the Existing Charter to remove the supermajority voting requirements for stockholders to amend certain provisions of the Company’s Existing Charter.

    At the time of the Special Meeting, Proposal 1 received support from:

    Votes
    For
     
    % of outstanding
    For
    766,481,570
     
    85.97%

    Approval of Proposal 1 requires the affirmative vote of the holders of at least 90% of the Company’s outstanding common stock.


    ➢
    The Special Meeting was adjourned with respect to Proposal 1 to allow for additional time for voting.

    Proposal 2. An amendment to the Existing Charter to establish stockholders’ meetings as the sole mechanism for approval of matters on which holders of common stock are required or permitted to vote.

    Votes
    For
     
    % of outstanding
    For
     
    Votes
    Against
     
    Votes
    Abstained
     
    Broker
    Non-Votes
    526,274,221
     
    59.03%
     
    255,565,697
     
    2,774,478
     
    0


    ➢
    Proposal 2 was approved.


    Proposal 3. An amendment to the Existing Charter to grant the Board the sole authority to fill board vacancies and newly created directorships.

    Votes
    For
     
     % of outstanding
    For
     
    Votes
    Against
     
    Votes
    Abstained
     
    Broker
    Non-Votes
    640,273,079
     
    71.82%
     
    143,348,025
     
    993,292
     
    0
     

    ➢
    Proposal 3 was approved.

    Proposal 4. An amendment to the Existing Charter to fix the size of the Board and to streamline the Existing Charter.

    Votes
    For
     
    % of outstanding
    For
     
    Votes
    Against
     
    Votes
    Abstained
     
    Broker
    Non-Votes
    624,929,832
     
    70.09%
     
    158,409,154
     
    1,275,410
     
    0


    ➢
    Proposal 4 was approved.

    Proposal 5. The proposal to adjourn the Special Meeting to a later date or time determined by the co-chairs of the Special Meeting, if necessary, to solicit additional proxies, if there are insufficient votes at the time of the Special Meeting to approve any of the other proposals.

    Votes
    For
     
    % of outstanding
    For
     
    Votes
    Against
     
    Votes
    Abstained
     
    Broker
    Non-Votes
    563,131,095
     
    63.16%
     
    219,418,201
     
    2,065,100
     
    0


    ➢
    Proposal 5 was approved.

    In addition, the Series I preferred stockholder voted “For” each of the proposals set forth above.
     
    As set forth in the Proxy Statement, all amendments to the Existing Charter approved at the Special Meeting will be effective as of the Sunset Date (as defined in the Proxy Statement), upon the filing and acceptance of the applicable Certificates of Amendment with the Secretary of State of the State of Delaware, which is expected to occur prior to the Sunset Date.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    KKR & CO. INC.
       
    Date: April 24, 2026
    By:
    /s/ Christopher Lee
     
    Name: Christopher Lee
      Title: Secretary
     
     

    Get the next $KKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KKR

    DatePrice TargetRatingAnalyst
    2/24/2026$137.00Outperform
    RBC Capital Mkts
    1/28/2026$144.00Hold → Buy
    HSBC Securities
    1/14/2026$131.00Buy → Hold
    TD Cowen
    12/11/2025$176.00Buy
    UBS
    7/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/9/2025$142.00Buy → Hold
    HSBC Securities
    6/30/2025$150.00Overweight
    Piper Sandler
    5/14/2025$150.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Kkr Alternative Assets Llc acquired $2,422,339 worth of Class I Common Stock (105,871 units at $22.88) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    7/2/26 4:05:37 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Kkr Alternative Assets Llc acquired $1,523,312 worth of Class I Common Stock (65,491 units at $23.26) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    6/2/26 4:05:53 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Kkr Alternative Assets Llc acquired $1,476,681 worth of Class I Common Stock (63,459 units at $23.27) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    5/4/26 4:05:48 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Director Dillon Mary N bought $2,021,586 worth of shares (22,225 units at $90.96) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:01 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on KKR with a new price target

    RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00

    2/24/26 7:55:00 AM ET
    $KKR
    Investment Managers
    Finance

    KKR upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00

    1/28/26 7:11:28 AM ET
    $KKR
    Investment Managers
    Finance

    KKR downgraded by TD Cowen with a new price target

    TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00

    1/14/26 8:26:34 AM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KKR Appoints Former Manulife CEO Roy Gori as Senior Advisor

    KKR, a leading global investment firm, today announced the appointment of Roy Gori, former President and Chief Executive Officer of Manulife, as a Senior Advisor to the firm. Mr. Gori, an accomplished leader in the global insurance and financial services industry, will advise KKR on strategic opportunities across global financial services and insurance with a focus on Asia Pacific and international markets. He will provide strategic counsel across insurance, wealth management, banking, distribution, and related financial services platforms. "We are pleased to welcome Roy to KKR as a Senior Advisor," said Joe Bae and Scott Nuttall, Co-Chief Executive Officers of KKR. "Roy is one of the mos

    7/21/26 6:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    Thomson Reuters and KKR Announce Joint Venture for Thomson Reuters Global Print Business

    TORONTO and NEW YORK, July 14, 2026 /CNW/ -- Thomson Reuters Corporation (TSX/Nasdaq: TRI) today announced that it has signed a definitive agreement to enter into a joint venture with KKR, a leading global investment firm. As part of the transaction, Thomson Reuters will sell a 51% stake in its Global Print business to capital accounts advised by KKR. Thomson Reuters will receive approximately $500 million in gross proceeds at closing and will retain a 49% equity interest in the joint venture. Thomson Reuters will also maintain intellectual property rights and full editorial control over its content portfolio. This new joint venture will hold an exclusive license to distribute the content in

    7/14/26 7:00:00 AM ET
    $TRI
    $KKR
    Publishing
    Consumer Discretionary
    Investment Managers
    Finance

    Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

    Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside Spero updates its cash runway guidance into the second half of 2029 CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healt

    7/14/26 6:02:00 AM ET
    $SPRO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    $KKR
    SEC Filings

    View All

    KKR & Co. Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    5/29/26 4:16:25 PM ET
    $KKR
    Investment Managers
    Finance

    KKR & Co. Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    5/28/26 4:15:25 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form S-3ASR filed by KKR & Co. Inc.

    S-3ASR - KKR & Co. Inc. (0001404912) (Filer)

    5/11/26 5:06:43 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/4/24 11:48:27 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G/A filed by KKR & Co. Inc. (Amendment)

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    2/13/24 6:32:37 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    KKR Appoints Former Manulife CEO Roy Gori as Senior Advisor

    KKR, a leading global investment firm, today announced the appointment of Roy Gori, former President and Chief Executive Officer of Manulife, as a Senior Advisor to the firm. Mr. Gori, an accomplished leader in the global insurance and financial services industry, will advise KKR on strategic opportunities across global financial services and insurance with a focus on Asia Pacific and international markets. He will provide strategic counsel across insurance, wealth management, banking, distribution, and related financial services platforms. "We are pleased to welcome Roy to KKR as a Senior Advisor," said Joe Bae and Scott Nuttall, Co-Chief Executive Officers of KKR. "Roy is one of the mos

    7/21/26 6:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Launches Allyntra, an Engineered Solutions Platform for Medical Technology and Precision Industries

    Robbie Atkinson appointed as CEO and Brian Highley appointed as Chairman KKR today announced the launch of Allyntra ("Allyntra" or the "Company"), a newly formed precision-engineered solutions platform serving medical technology and other precision end markets. Allyntra builds on KKR’s existing investment in Precipart through its Health Care Strategic Growth Fund II, with Precipart serving as one of the foundational businesses within the platform. KKR is committing meaningful additional capital to support Allyntra’s growth by acquiring and integrating complementary best-in-class businesses and through continued investment in innovation and commercial expansion. This press release feature

    7/9/26 6:59:00 AM ET
    $KKR
    $PRM
    Investment Managers
    Finance
    Major Chemicals
    Industrials

    KKR-led Consortium Drives Further Investment in Sylvan

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Financials

    Live finance-specific insights

    View All

    FSK Announces Earnings Release and Conference Call Schedule for Second Quarter 2026

    PHILADELPHIA and NEW YORK, July 9, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK) announced today plans to release its second quarter 2026 results before the opening of trading on the New York Stock Exchange on Thursday, August 6, 2026. FSK will host its second quarter 2026 results conference call via live webcast on Thursday, August 6, 2026 at 9:00 a.m. (Eastern Time). All interested parties are welcome to participate and can access the live webcast from the For Investors section of FSK's website at www.fskkrcapitalcorp.com under Events & Presentations or through the foll

    7/9/26 4:20:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    KKR & Co. Inc. to Announce Second Quarter 2026 Results

    KKR & Co. Inc. (NYSE:KKR) announced today that it plans to release its financial results for the second quarter 2026 on Thursday, July 30, 2026, before the opening of trading on the New York Stock Exchange.A conference call to discuss KKR’s financial results will be held on Thursday, July 30, 2026 at 9:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Center section of KKR’s website at https://ir.kkr.com/events-presentations/. A replay of the live broadcast will be avail

    7/1/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

    - Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s 30-day VWAP) - The financing significantly strengthens the Company’s balance sheet, enabling it to efficiently allocate capital across its highest return opportunities - The financing comes at a pivotal moment for the Company, as Attruby® continues to grow into a multi-billion-dollar blockbuster drug, and as BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months across BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigr

    7/1/26 7:30:00 AM ET
    $BBIO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance